Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPI-1620 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SPI-1620 | EXPERIMENTAL | SPI-1620 an endothelin B agonist |
| Name | Type | Description |
|---|---|---|
| SPI-1620 | DRUG | SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds |
Inclusion Criteria: All of the following inclusion criteria must be met prior to participation in this study 1. The patient must sign an informed consent. A signed consent form is required prior to the performance of any protocol-related procedures or assessments. 2. The patient must be \>= 18 yea...
Top 20 of 23 competitors
SPI-1620 is an investigational small molecule being studied for the treatment of carcinoma, specifically in patients with recurrent or progressive carcinoma. It is in Phase 1 clinical development and has not been approved by the FDA.
SPI-1620 is an endothelin B receptor agonist. It works by activating the endothelin B receptor, which is involved in various cellular processes. This mechanism is being explored for its potential anti-cancer effects in patients with carcinoma.
SPI-1620 is being developed by Assertio Holdings, Inc., a company traded on the NASDAQ under the ticker symbol ASRT. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
SPI-1620 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials.
SPI-1620 has been studied in one clinical trial, identified as NCT00613691. This was a Phase 1, open-label, ascending dose study that evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma. The trial enrolled 36 participants and has been completed.
SPI-1620 is an endothelin B agonist, meaning it activates the endothelin B receptor. It is a specific investigational drug being developed by Assertio Holdings, Inc. for the treatment of carcinoma. The drug is not known by any other brand names.